Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19
10.13422/j.cnki.syfjx.20201438
- VernacularTitle:连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察
- Author:
Hui-min SUN
1
;
Feng XU
2
;
Ling ZHANG
3
;
Cong WEI
4
;
Jie-yong CHEN
5
;
Qiu-xin WANG
6
;
Zhen-hua JIA
7
Author Information
1. Tangshan Hospital of Traditional Chinese Medicine，Tangshan063000，China
2. Cangzhou People's Hospital，Cangzhou061000，China
3. Hebei Thoracic Hospital，Shijiazhuang050041，China
4. National Key Laboratory of Luobing Research and Innovative Chinese Medicine， Shijiazhuang050035，China
5. The Third People's Hospital of Hengshui City，Hengshui053000，China
6. Tangshan Infectious Diseases Hospital，Tangshan063000
7. Hebei Yiling Pharmaceutical Research Institute， Shijiazhuang050035，China
- Publication Type:Research Article
- Keywords:
coronavirus disease 2019 （COVID-19）;
Lianhua Qingke granule;
cough;
randomized and controlled;
clinical study
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(14):29-34
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of traditional Chinese medicine Lianhua Qingke granule （LH granule）in the treatment of coronavirus disease 2019（COVID-19）. Method:A randomized controlled method was used in this clinical study. The subjects were confirmed COVID-19 patients over 18 years old with cough symptoms，and the diagnosis is based on Diagnosis and Treatment Protocol for COVID-19 （Trial Version 6）. The subjects were randomized to usual treatment （control group） or in combination with LH granule （1 bag，thrice daily） for 14 days. The primary endpoint was the rate of cough recovery. Result:57 subjects were included in this study， including 25 in the control group and 32 in the observation group. The recovery rate of cough in observation group was 90.6%（29/32）， which was significantly higher than 64.0%（16/25）in the control group （P<0.05）. The effective time of cough treatment was significantly earlier than that of the control group （P<0.05）， the median time to cough recovery was markedly shorter in treatment group （P<0.05）. The recovery rate of expectoration in observation group was 94.7% （18/19）， which was significantly higher than 57.1%（8/14）in the control group （P<0.05）. The effective time of expectoration treatment was significantly earlier than that of the control group （P<0.05）， and the median time to expectoration recovery was markedly shorter in treatment group （P<0.05）. The improvement rate of CT in the observation group was 96.9% （31/32）， which was significantly higher than 72% （18/25） in the control group （P<0.05）. After treatment， the oxygenation index of the two groups increased in varying degrees， and the increase rate of the observation group was significantly higher than that of the control group （P<0.05）. There was no significant difference in the recovery rate of fever， fatigue， dry pharynx and sore throat between the observation group and the control group， and it showed that LH had a better improvement trend on the basis of usual treatment. Conclusion:On the basis of routine treatment，LH can significantly improve the symptoms of cough and expectoration of COVID-19 patients， shorten the duration of cough and expectoration symptoms， reduce lung pathological damage， improve respiratory function， and improve the symptoms of fever， fatigue， dry pharynx and sore throat.
